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Paricalcitol, an analog of vitamin D, is used as a drug for the prevention and treatment of secondary hyperparathyroidism. In this 
paper, a new strategy for the synthesis of paricalcitol is described. This approach includes three main improvements: one-pot re-
gioselective ozonization cleavage of the side-chain and methylene at C-19, free-radical reduction removal of the OH group 
formed at C-19, and side-chain assembly using a Wittig reaction. These are all new strategies for the synthesis of 19-nor-vitamin 
D2 compounds. 
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Paricalcitol (1, Figure 1), a second-generation vitamin D 
receptor (VDR) activator, has been developed as a drug for 
the prevention and treatment of secondary hyperparathy-
roidism (SHPT) and of period III and IV chronic kidney 
diseases (CDK) [1]. The effect of paricalcitol on intestinal 
calcium resorption is less than that of calcitriol; this avoids 
undesirable hypocalcaemia [2]. Paricalcitol also retains sig-
nificant immunomodulatory activity, comparable to that of 
calcitriol [3]. The immunomodulatory potency of paricalci-
tol makes it a drug of interest in the therapy of chronic im-
mune-mediated inflammatory diseases. 
Paricalcitol is of wide interest because of its known and 
potential applications. The original synthesis [4,5] used a 
convergent strategy. Three key parts were prepared respec-
tively from vitamin D2, quinic acid, and methyl 2-     
methyl-3-hydroxypropionate, and assembled to form pari-
calcitol in 19 steps. Another synthesis [6] started from er-
gosterol and used ozonization, with Julia coupling as the 
key steps. A modification of the introduction of the side- 
chain of paricalcitol was reported by Ng and co-workers [7], 
who used a Wittig-Horner reaction instead of Julia olefina-
tion. The most recent synthesis [8] still started from vitamin 
D2 and involved 17 steps. The assembly of side-chains and  
 
Figure 1  Structure of paricalcitol. 
cleavage of the methylene group on ring A of vitamin D2 
were achieved by ozonization/Julia olefination and dihy-
droxylation/oxidation with NaIO4, respectively.  
Large-scale, efficient, convenient synthesis of paricalci-
tol is still a challenge. We therefore tried to find an efficient 
synthetic method. First, we tried to improve the main con-
version steps, especially removal of the C-19 methylene 
group and assembly of the side-chain. It was found that the 
side-chain and C-19 methylene can be cleaved selectively in 
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one-pot ozonization instead of by ozonization/dihydroxy-  
lation/oxidation cleavage of NaIO4; the formed C-19 OH 
group was removed by free-radical reduction instead of re-
duction using LiAlH4, and the side-chain was assembled 
using a Wittig reaction instead of Julia coupling/olefination. 
These improvements made the synthesis more convenient 
and efficient. 
The synthesis started from commercially available vita-
min D2, which has a skeleton similar to that of paricalcitol. 
Because both the methylene group and the side-chain can be 
cleaved by ozonization, cleavage can be performed in one 
pot using ozone. Reaction of vitamin D2 with p-toluene- 
sulfonyl chloride (TsCl) in pyridine gave tosylate 3 in 88% 
yield. Treatment of 3 with K2CO3 in methanol gave com-
pound 4 in 67% yield [9], in which one double bond    
was protected and the methylene group on ring A and the 
double bond of the side-chain remained. Allylic oxidation 
of 4 to introduce 1-α-OH proceeded by allylic oxidation 
with SeO2 [10]. It was found that t-butyl hydroperoxide 
(TBHP) is a better co-oxidant than N-methylmorphine 
N-oxide (NMO). In dichloromethane (CH2Cl2)/methanol 
(MeOH) (3:1, v/v) as solvent and using SeO2/TBHP and 
SeO2/NMO as oxidants, 5 yielded in 58% and 40% yields 
from 4, respectively. Importantly, both of these two oxida-
tions gave a single 1-α-OH product 5 after column chroma-
tography (Figure 2).  
The first important step in the synthesis is the one-pot 
ozonization of the methylene group and the side-chain. 
Compound 5 was treated with either MeOCH2Cl and diiso-
propylethylamine (DiPEA) in CH2Cl2 or acetic anhydride 
(Ac2O) and pyridine (Py) in CH2Cl2 or t-butyldimethylsilyl 
chloride (TBDMSCl) and imidazole in N,N-dimethy-  
lformide (DMF) to protect the OH group. The correspond-
ing protected products 6a, 6b, and 6c were formed in 90%, 
86%, and 80% yields, respectively. The ozonization of each 
of 6a, 6b, and 6c was carried out in CH2Cl2/MeOH (1:1, v/v) 
at –65°C. After the starting material had all reacted, NaBH4 
was added to quench the reaction. Compounds 7a1), 7b, and 
7c were obtained from the corresponding substrates in 62%, 
40%, and 52% yields, respectively, as single isomers (Fig-
ure 3). Neither the configurations of 7a–7c, nor those of the 
corresponding subsequent compounds 8–13, are known. 
The second challenge in the synthesis is the removal of 
the OH group on C-19 of compound 7a. First, 7a was re-
acted with Ac2O and pyridine in CH2Cl2 to protect the pri-
mary OH. In accordance with the literature [11], 8a was
 
 
Figure 2  Synthesis of intermediates 7a–7c. Reagents and conditions: a) TsCl, pyridine, rt, 10 h, 88%; b) K2CO3, MeOH, reflux, 5 h, 67%; c) SeO2, TBHP, 
CH2Cl2, MeOH, reflux, 58%; d) MeOCH2Cl, DiPEA, CH2Cl2, rt, 7 h, 90% yield for 6a; Ac2O, pyridine, CH2Cl2, rt, 6 h, 86% yield for 6b; TBDMSCl, imid-
azole, DMF, 80% yield for 6c; e) i. O3, CH2Cl2, MeOH; ii. NaBH4; –78°C, 62% for 7a, 40% for 7b, and 52% for 7c. 
 
Figure 3  Removal of OH group on ring A of 8a. Reagents and conditions: f) Ac2O, pyridine, CH2Cl2, rt, 3 h, 85% for 8a; TBDMSCl, imidazole, DMF, rt, 
1 h, 78% for 8b; g) 9a: MsCl, Et3N, 0°C, 1 h; 9b: i. NaH, THF, CS2, reflux, 3 h; ii. MeI, reflux, 3 h; 67% for 9b; 9c: 1,1’-diimidazole carbonyl, DMAP, 
CH2Cl2, 1 h, 84% for 9c; 9d: MsCl, Et3N, CH2Cl2; h) LiAlH4, THF, rt, for 9a and 9d; Bu3SnH, AIBN, toluene, reflux, for 9b and 9c. 
                                     
1) The spectrum data of 7a: 1H NMR (300 MHz, δ) 0.57 (3H, s), 0.65 (1H, m), 0.80–0.87 (2H, m), 1.04 (3H, d, J = 6.6 Hz), 1.27–1.35 (3H, m), 
1.47–1.55 (3H, m), 1.61–1.67 (3H, m), 1.84–2.01 (6H, m), 2.81 (1H, d, J = 10.5 Hz), 3.05 (1H, s), 3.16 (3H, s), 3.34 (3H, s), 3.50 (1H, m), 3.62 (1H, dd, J = 
2.1, 10.5 Hz), 3.65 (1H, dd, J = 2.4, 6.9 Hz), 3.98 (1H, d, J = 4.2 Hz), 4.58 (1H, d, J = 9.6 Hz), 4.59 (2H, m), 4.75 (1H, d, J = 9.6 Hz). 13C NMR (75 MHz, δ) 
9.6, 11.8, 16.8, 18.2, 22.2, 23.6, 27.1, 29.3, 31.0, 34.3, 39.0, 40.3, 45.5, 52.8, 55.5, 55.6, 67.7, 72.6, 73.9, 77.2, 96.2, 119.3, 144.0. ESI-HRMS (m/z) [M+Na+] 
431.2763 (Calc. 431.2768). 
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mesylated with methanesulfonyl chloride (MsCl) and tri-
ethylamine (Et3N) in CH2Cl2 to form compound 9a and the 
crude 9a was subsequently reduced using LiAlH4 in THF 
before purification. Unfortunately, these two reaction steps 
were messy, and 10 was not found. Detailed investigations 
found that very little 9a was formed in the mesylation. To 
avoid the effect of the actyl group in the reduction, 8b was 
prepared from 7a in 78% yield. The mesylation of 8b, fol-
lowed by reduction of 9b, was also messy and failed to give 
10. Investigation of the side-products proved that the 
three-membered ring is unstable under these reductive con-
ditions. So, another approach was proposed, as shown in 
Figure 4. 
Compound 8a was treated with acetic acid (AcOH) in 
dimethyl sulfoxide (DMSO) and 11 was formed in 72% 
yield as a single isomer after purification by column chro-
matography [12–15]. The double-bond configuration of 
compound 11 is not known for certain and those of the sub-
sequent products 12–19 are also unclear. The protection of 
11 with MeOCH2Cl/DiPEA gave an OH-free product in 
which the two OH groups of 11 were protected. So, a bulky 
group TBDMS was used as the protection group and 12 was 
obtained in 75% yield. Procedures similar to the protection 
of 8a converted 12 to 13a–13c. Compounds 13a, 13b, and 
13c were prepared in 38%, 57%, and 78% yields, respec-
tively. Compound 13a was reduced with LiAlH4 in THF 
and only a trace of 14 was found. Free-radical reduction of 
13b with tributyltin hydride (Bu3SnH) and azodiisobutrnitrile 
(AIBN) in toluene under reflux [16] gave the desired dehy-
droxylated product 14 in 48% yield. However, the reduction 
of 13c only gave 12 along with some useless products. 
At this point, the skeleton of the target compound had 
been constructed. The last important step is to introduce a 
new side-chain. Julia olefination [8] and the Wittig reaction 
[7] are general methods for this kind of conversion. As in 
the scheme shown in Figure 4, 14 was deprotected with 
K2CO3 in MeOH, followed by Swern oxidation; aldehyde 
162) was formed in 62% yield from 14. The side-chain 17 
was prepared from ester 20. Grignard reaction of 20 with 
3.0 equivalents of MeMgBr in Et2O gave 21 in quantitative 
yield. Compound 21 reacted with TsCl and pyridine in 
CH2Cl2 to form tosylate 22 in 85% yield [17]. Nucleophilic 
substitution of 22 with NaI in acetone gave 23 in 77% yield. 
After protection, 243) was heated with PPh3, without a sol-
vent, and 17 was formed. Trituration of the reaction mixture 
with Et2O and CH2Cl2 by turns gave the purified side-chain 
17. The yields of 17 from 23 are 30%–60%, depending on 
the protecting group. Sulfone 25 was prepared according to 
the literature method [18]. 
As the scheme shown in Figure 4, compound 17a was  
 
 
Figure 4  Alternative method for removing the OH group of 8a. Reagents and conditions: i) AcOH, DMSO, 50°C, 1 h, 72%; j) TBDMSCl, imidazole, 
DMF, rt, 2 h, 75%; k) 13a: MsCl, Et3N, CH2Cl2, 0°C; 13b: i. NaH, THF, CS2, reflux, 3 h; ii. MeI, reflux, 3 h, 57% for 13b; 13c: 1,1’-diimidazole carbonyl, 
DMAP, CH2Cl2, rt, 78% for 13c; l) LiAlH4, THF, rt, for 13a; Bu3SnH, AIBN, toluene, reflux, 1 h, 48% for 13b; m) K2CO3, MeOH, reflux, 3 h; n) (COCl)2, 
DMSO, CH2Cl2, Et3N, 78°C, 62% for two steps; o) i. n-BuLi, THF, 78°Crt, 1 h; ii. 17, THF, 10 h, 72% for 18a, 63% for 18b; p) 19a: PPTs, 95% EtOH, 
reflux, 2 h, 70%; 1: ZrCl4, i-PrOH, reflux, 5 h, 65%. 
                                 
2) The spectrum data of 16: 1H NMR (300 MHz, δ) 0.05 (6H, s), 0.57 (3H, s), 0.86 (9H, s), 1.12 (3H, d, J = 6.9 Hz), 1.40 (1H, m), 1.50–1.75 (8H, m), 
1.872.02 (4H, m), 2.062.16 (1H, m), 2.292.43 (3H, m), 2.54 (1H, dd, J = 6.0, 14.1 Hz), 2.82 (1H, dd, J = 3.9, 10.5 Hz), 3.34 (3H, s), 3.954.03 (2H, m), 
4.64 (2H, dd, J = 6.6, 9.3 Hz), 5.84 (1H, d, J = 11.1 Hz), 6.20 (1H, d, J = 11.7 Hz), 9.57 (1H, s). 13C NMR (75 MHz, δ) 4.7, 12.4, 13.5, 18.1, 22.6, 23.1, 25.8, 
26.4, 28.6, 33.5, 40.1, 40.7, 45.8, 46.0, 49.7, 51.3, 55.2, 55.4, 67.8, 72.7, 94.8, 116.2, 121.8, 133.5, 140.5, 205.0. ESI-HRMS (m/z) [M+K+] 529.3118, 
[M+Na+] 513.3370 (Calc. 513.3371), [M+NH4
+] 508.3826. 
3) The spectrum data of 24c: 1H NMR (300 MHz, δ) 1.08 (3H, d, J = 5.7 Hz), 1.12 (3H, s), 1.23 (3H, s), 1.97 (1H, m), 2.85 (1H, dd, J = 9.3, 11.1 Hz), 
3.35 (3H, s), 3.68 (1H, dd, J = 1.8, 9.3 Hz), 4.67 (2H, m). 
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Figure 5  Side-chain preparation. Reagents and conditions: q) MeMgBr, Et2O, reflux, 3 h, 98%; r) TsCl, pyridine, rt, 2 h, 85%; s) NaI, acetone, reflux, 10 h, 
77%; t) 3, 4-DHP, cat. p-TsOH, CH2Cl2, rt, overnight, 83% for 24a; MeOCH2Cl, DiPEA, CH2Cl2, rt, 4 h, 88% for 24b; u) PPh3, 100°C, 40 h, 60% for 17a 
and 66% for 17b. 
deprotonated with n-BuLi at –78°C, and then the generated 
anion reacted with 16 in situ to form 18a in 72% yield in a 
4:3 trans/cis ratio. The mixture cannot be separated by 
flash silica-gel column chromatography and the trans/cis 
ratio was determined by 1H NMR. Other strong bases such 
as MeLi, PhLi, and potassium t-butoxide (t-BuOK) did 
work in this reaction, but did not improve the conversion 
rate or the selectivity. Similar results were also observed in 
the reaction of 17b with 16. The yield of 17b was 63%. 
Unexpectedly, a similar reaction of 16 and 25, using a liter-
ature procedure [18], did not give any useful products.  
Removal of the protecting groups on 18a and 18b is a 
challenge. Many methods, including protonic conditions 
and Lewis acid conditions, have been reported to remove 
SiMe2Bu
t, THP, THF, and CH2OMe. However, the THP of 
18a and THF of 18b cannot be removed. Reactions with 
p-toluenesulfonic acid (p-TsOH) in aqueous ethanol, 3 
mol/L HCl in methanol, MgBr2 in THF, Dowex resins, 
ZrCl4 in i-propanol (i-PrOH), pyridium p-toluenesulfonate 
(PPTs)in ethanol (EtOH), Py·HF in THF, tetrabutylammo-
nium fluoride (TBAF) in tetrahydrofuran (THF), etc. simply 
converted 18a to 19a. Strong Lewis acids such as AlCl3 and 
BF3·Et2O did not remove THP and THF, and also decom-
posed most of the substrate. After screening a great many 
reagents, solvents, and reaction temperatures, 14) was ob-
tained in 65% yield by refluxing 18b with ZrCl4 in i-PrOH.  
In conclusion, a new synthesis of paricalcitol was 
achieved in 14 steps. This approach had major improve-
ments on previous syntheses. First, the C-19 methylene 
group was removed by ozonization and free-radical reduc-
tion; this is more efficient strategy than that trough dihy-
droxylation, cleavage, protection, and reduction. Second, 
the side-chain was assembled by ozonization and a Wittig 
reaction rather than by ozonization, Julia coupling, and ole-
fination; this is a shorter conversion and is also heavy-metal- 
free conversion. More importantly, the ozonization of the 
side-chain and methylene group was a one-pot reaction; this 
is the first use of selective ozonization in the synthesis of 
paricalcitol. This synthesis is not only important for the re-
search on and development of paricalcitol, but is also of 
value in research on vitamin D analogs. This is the shortest 
synthesis of paricalcitol to date, and will be applicable after 
further modifications. 
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4) The spectrum data of paricalcitol (1): 1H NMR (300 MHz, δ) 0.58 (3H, s), 0.99 (6H, m), 1.18 (3H, s), 1.26 (3H, s), 1.38 (1H, m), 1.46 (3H, m), 
1.67–1.83 (8H, m), 1.92–2.00 (3H, m), 2.19–2.27 (2H, m), 2.48 (1H, m), 2.71 (1H, m), 2,79 (1H, m), 4.05 (1H, m), 4.11 (1H, m), 5.18 (1H, dd, J = 9.9, 11.1 
Hz), 5.35 (1H, dd, J = 9.6, 11.1 Hz), 5.84 (1H, d, J = 11.1 Hz), 6.30 (1H, d, J = 11.1 Hz). 13C NMR (75 MHz, δ) 12.4, 16.4, 21.7, 21.3, 22.2, 25.4, 26.6, 26.9, 
27.7, 28.9, 34.0, 37.0, 40.3, 42.1, 42.7, 44.6, 45.6, 56.2, 60.4, 67.1, 72.7, 115.3, 123.2, 128.2, 131.3, 138.3, 142.7. ESI-HRMS (m/z) [M+NH4
+] 434.3623 
(Calc. 434.3629). 
